Study questions animal efficacy data behind trials.
Study questions animal efficacy data behind trials.
复制标题
研究质疑试验背后的动物功效数据。
作者：
Emma Yasinski
在生物医学研究人员在人体上测试新疗法之前，通常会要求审查小组不仅考虑风险，还要考虑潜在的好处。这种“治疗潜力”几乎总是基于动物的临床前研究。但一项新的研究表明，审查小组可能很难评估这些研究，因为他们没有收到足够的信息。研究人员检查了向德国三个机构审查委员会提供的 100 多本小册子，发现绝大多数都包含未发表或可能容易受到偏见的动物功效研究。研究小组报告说，不那么讨人喜欢的研究似乎经常被遗漏。但未参与该研究的研究人员对问题的严重性存在分歧。
Before biomedical researchers can test a new therapy in humans, a review panel is typically asked to consider not just the risks, but also the potential benefits. This "therapeutic potential" is almost always based on preclinical studies in animals. But a new study suggests that review panels may have a hard time evaluating those studies because they don9t receive nearly enough information. Researchers examined more than 100 brochures provided to three institutional review boards in Germany and found that the vast majority included animal efficacy studies that were unpublished or potentially vulnerable to bias. And less flattering studies seemed left out frequently, the team reports. But researchers not involved in the study are divided on the severity of the problem.